Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Langslet G, Nyström T, Vistisen D, Carstensen B, Grip ET, Casajust P, Tskhvarashvili G, Hoti F, Klement R, Karlsdotter K, Tuovinen M, Ofstad AP, Lajer M, Shay C, Koeneman L, Farsani SF, Niskanen L, Halvorsen S. Langslet G, et al. Among authors: koeneman l. J Diabetes Res. 2024 Oct 12;2024:6142211. doi: 10.1155/2024/6142211. eCollection 2024. J Diabetes Res. 2024. PMID: 39430801 Free PMC article.
Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. Among authors: koeneman l. Diabetologia. 2024 Jul;67(7):1328-1342. doi: 10.1007/s00125-024-06126-3. Epub 2024 Mar 21. Diabetologia. 2024. PMID: 38509341
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. Among authors: koeneman l. Cardiovasc Diabetol. 2024 Mar 18;23(1):103. doi: 10.1186/s12933-024-02190-6. Cardiovasc Diabetol. 2024. PMID: 38500096 Free PMC article. No abstract available.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: koeneman l. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: koeneman l. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. Among authors: koeneman l. JAMA Netw Open. 2022 Oct 3;5(10):e2237606. doi: 10.1001/jamanetworkopen.2022.37606. JAMA Netw Open. 2022. PMID: 36264574 Free PMC article.
Precision Dosing of Rapid-Acting Insulin Matters.
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Aanstoot HJ, et al. Among authors: koeneman l. Diabetes Technol Ther. 2020 May;22(5):346-351. doi: 10.1089/dia.2019.0374. Epub 2020 Mar 3. Diabetes Technol Ther. 2020. PMID: 32125891 Review.